新闻

RapAdmin

JonathanTortoise
JonathanTortoise2752×1536 458 KB

Researchers sequenced the genome and DNA methylation pattern of Jonathan, an Aldabra giant tortoise estimated to be 194 years old, and compared his methylation with four other Aldabras aged 5 to about 90. Jonathan shows the usual marks of epigenetic aging: genome-wide loss of methylation and rising disorder in his methylation pattern. The exception is a set of 272 gene promoters where his pattern is as orderly as a juvenile’s, and that set is rich in mitochondrial, RNA-processing and DNA-repair genes. The authors propose that protecting these promoters from epigenetic noise helps explain his survival.

Jonathan, an Aldabra giant tortoise living on the South Atlantic island of St Helena, is thought to be 194 years old. That makes him the oldest known land animal and roughly a century past the usual upper limit for his species. A team led by the Kallel Foundation in Nashville has now read both his genome and his methylome, the pattern of chemical tags on DNA that helps decide which genes are switched on.

The headline result is less flattering than the tortoise’s reputation suggests. Jonathan has not escaped epigenetic aging. Compared with a 5-year-old juvenile, his DNA has lost methylation across most of the genome, and about 91 percent of the regions that differ between the two animals carry fewer tags in Jonathan. Genes that guide embryonic development have gained tags instead. Both changes are textbook signs of aging in mammals, humans included.

The researchers also measured methylation entropy, a score of how disordered the tagging pattern has become. Tidy patterns are a feature of young cells. Disorder accumulates over time and, when it reaches the control regions of genes known as promoters, it is linked to erratic gene activity. Across five tortoises aged 5 to 194, whole-genome entropy rose in step with age, and Jonathan sat at the top.

The interesting part is the exception. In 272 gene promoters, Jonathan’s entropy was as low as that of the two youngest animals, while two tortoises of about 90 showed clear disorder. That set of 272 was unusually rich in genes that build and run mitochondria, the cell’s power plants, including parts of the respiratory chain and the scaffolding that shapes the inner mitochondrial membrane. Genes for RNA processing and DNA repair also featured.

From this the authors sketch a model: orderly promoters keep mitochondrial genes firing steadily, a steady energy supply pays for DNA repair, and good repair in turn keeps those promoters orderly. A similar promoter pattern has been reported in long-lived Chinese people, which gives the idea some support from a second species.

The genome itself yielded a long list of candidates. Jonathan carries 770 genes flagged as positively selected and 287 genes with protein-changing variants not seen in the other tortoises examined, many in DNA repair, telomere maintenance and insulin signaling. Like other giant tortoises, he has a duplicated copy of LAMTOR4, a gene in the mTOR growth pathway that rapamycin targets.

The caveats are large. This is one exceptional animal compared with four others, using cheek swabs because St Helena officials would not allow a blood draw. No one measured gene activity, mitochondrial performance or anything else that would show the tidy promoters matter. The 272 genes were selected precisely because they fit the pattern the authors were looking for, and only about a tenth of the tortoise’s promoters could be read at all. The authors acknowledge their data cannot establish cause.

What the study offers is a hypothesis worth testing in other long-lived animals: that surviving to an extreme age may depend less on stopping the epigenetic clock than on protecting a small set of genes from its noise.

Insights

There is nothing in this paper you can take, eat or do. What it does offer is a sense of scale and a direction. Jonathan’s 194 years are about 2.1 times the estimated upper limit for his species (93.7 years) and 2.4 times the mean (80.5 years). The human equivalent would be someone living well past 200. Yet his overall epigenetic disorder still rose with age, so extreme survival did not require a stopped clock.

The one distinctive signal covers 272 of 2,895 readable gene promoters, or 9.4 percent. Of those, 35 (13 percent) are mitochondrial. In that subset, the two tortoises of about 90 showed roughly three to four times Jonathan’s entropy (values read from the figure). The subset was chosen to show exactly that contrast, so the gap is inflated.

The practical reading is modest. The result adds weak, indirect support to the view that preserving mitochondrial function matters in late life. The interventions with human evidence for that remain the familiar ones, chiefly regular aerobic and resistance exercise. This paper does not test them and does not strengthen the case for any supplement.

Context/Source

  • Open Access Paper: Epigenetic insights into extreme longevity in the world’s oldest terrestrial animal, Jonathan
  • Lead institutions: Kallel Foundation (Nashville), Igenbio Inc. (Chicago) and Vanderbilt University Medical Center, with collaborators at UCLA, Harvard Medical School, University of Minnesota, Technical University of Munich, University of Cambridge, University of Copenhagen and the St Helena Government
  • Country: USA (lead), with Germany, UK, Denmark and St Helena
  • Journal: Science Advances, published 7 October 2026
  • Impact evaluation: The impact score of this journal is 13.9 (Journal Impact Factor, 2025 data year, released June 2026), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

相关阅读：

RapAdmin

ipragliflozin
ipragliflozin2752×1536 447 KB

A Chinese team built a single-cell “aging clock” from three published human skin datasets and found that the small blood vessels of the skin carry the strongest age signal. They propose that, under chronic inflammation, vessel-lining endothelial cells drift toward a pericyte-like, senescent state marked by the motor protein MYO1B and controlled by the transcription factor ETS1. A computer screen of a drug library flagged the SGLT2 inhibitor ipragliflozin as an ETS1 binder. The drug lowered MYO1B and senescence markers in a cultured endothelial cell line and partially restored epidermal thickness in young rats given D-galactose to mimic aging.

Skin aging is usually told as a story about collagen, sunlight and fibroblasts. This paper argues that the plumbing matters more than we thought.

The researchers pooled three public single-cell RNA datasets of human skin and trained a machine-learning model to guess a donor’s age from gene activity in each cell type. Across 18 donors, predicted age tracked real age reasonably well. The interesting part was where the signal came from. Blood vessel endothelial cells, lymphatic endothelial cells and pericytes, the support cells that wrap around capillaries, were the cell types whose gene activity most consistently tracked age.

Within the pericytes, one subgroup was more common in older donors and carried high levels of MYO1B, a motor protein tied to the cell’s internal skeleton. When the team lined up endothelial cells and these pericytes computationally, they formed a continuous gradient rather than two separate islands. The authors read this as endothelial cells slowly converting into pericyte-like cells with age, a process they call endothelial-to-pericyte transition, or EndoPT.

To test the idea, they bathed a human endothelial cell line in two inflammatory signals, TGF-beta1 and IL-1beta, for a week. The cells lost an endothelial marker, gained pericyte markers including MYO1B, and stained positive for senescence. Silencing the transcription factor ETS1 cut MYO1B expression by roughly 70 percent and reduced senescence staining, and ETS1 was found sitting on the MYO1B gene’s promoter. That gives a plausible chain: inflammation switches on ETS1, ETS1 switches on MYO1B, and the cell shifts identity and senesces.

Then comes the leap. The team docked more than 4,000 drugs against a predicted structure of ETS1. Ipragliflozin, a diabetes drug sold in Japan, ranked third. A binding assay showed the drug sticking to purified ETS1 in a concentration-dependent way, and in cells it lowered MYO1B and two senescence genes. In rats given D-galactose for eight weeks, a standard chemical shortcut for mimicking aging, daily ipragliflozin left the epidermis about 50 percent thicker than in untreated D-galactose rats, though still far thinner than in healthy animals.

The big idea is worth taking seriously: skin aging may be driven partly by a deteriorating vascular niche, and that niche may be druggable. Independent work already links SGLT2 inhibitors to senescent-cell clearance and vascular protection.

But the gap between the idea and the proof is wide. The human evidence comes from 18 donors in the clock and 15 tissue samples whose body sites differ between the young and old groups. The cell identity shift is inferred from snapshots, not tracked in living tissue. The rats were juveniles, all male, six per group, and the study never checked whether the drug’s known whole-body effects on glucose and metabolism explain the skin result. The claim that ipragliflozin works by binding ETS1, rather than through its ordinary pharmacology, rests on computer modeling and one binding experiment with no reported affinity.

Insights

To put the headline result in real-world terms: D-galactose thinned rat epidermis from about 14 micrometers to about 5 micrometers. Ipragliflozin brought it back to about 8 micrometers. That is a gain of roughly 2.6 micrometers, or about 30 percent of the lost thickness recovered. Treated skin was still around 43 percent thinner than healthy skin. The standardized effect size (Cohen’s d) works out to about 1.4, which is “large” on paper, meaning a randomly picked treated rat would have thicker epidermis than a randomly picked untreated one about 85 percent of the time. With only six rats per group, though, the plausible range for that effect runs from trivial to enormous. All of these figures are my estimates read from the paper’s bar chart, since the authors give no numbers in the text.

The rat dose translates to roughly 110 mg per day for a 70 kg adult, about double the standard 50 mg clinical dose.

The practical takeaway is modest: vascular health and chronic inflammation are reasonable things to care about for skin aging, and people already on an SGLT2 inhibitor for medical reasons have one more speculative reason to consider.

Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical and commonly sold under the brand name Suglat, is approved and commercialized in Japan, South Korea, Russia, Taiwan and China. Ipragliflozin is NOT available in India.

Context and Source

  • Open Access Paper: Multimodal profiling uncovers an aging-associated ETS1-MYO1B vascular niche responsive to ipragliflozin
  • Institutions: Department of Dermatology, Shengjing Hospital, China Medical University, Shenyang (lead); and others.
  • Country: China
  • Journal: Frontiers in Cell and Developmental Biology, published 25 September 2026
  • Impact evaluation: The impact score of this journal is 5.3 (Journal Impact Factor; CiteScore 9.9), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

RapAdmin

BowheadWhale
BowheadWhale2752×1536 434 KB

This study investigates the evolutionary adaptations of the FOXO gene family across 137 mammalian species, identifying unique structural mutations in long-lived mammals such as the bowhead whale. By overexpressing bowhead whale FOXO3 and FOXO4 variants in human HeLa cancer cells, researchers demonstrated that these specific proteins predominantly localize to the nucleus and significantly suppress tumor proliferation, migration, and invasion compared to their mouse counterparts. The findings indicate that evolutionary modifications in FOXO proteins enhance their transcriptional activity and tumor-suppressive functions, contributing to the extreme longevity and cancer resistance observed in certain mammalian lineages.

A central question in aging research is why large, long-lived animals do not invariably die of cancer, a phenomenon known as Peto’s Paradox. This paper targets the FOXO family of transcription factors, well-known nodes in longevity and stress resistance pathways, to determine if evolutionary changes in these genes explain the extreme lifespans of species like the 211-year-old bowhead whale.

The research team analyzed FOXO1, FOXO3, FOXO4, and FOXO6 across 137 mammals. They identified 18 positively selected mutation sites unique to long-lived species, suggesting an adaptive evolutionary pressure on these specific genetic sequences. To move beyond computational correlation, the researchers engineered human cervical cancer cells (HeLa) to overexpress either the bowhead whale versions of FOXO3 and FOXO4 or the standard short-lived mouse versions.

The physiological differences were distinct. Whale FOXO proteins naturally migrated into the cell nucleus, the command center where transcription factors must reside to be active. In contrast, mouse FOXO proteins remained largely trapped in the cytosol. Once in the nucleus, the whale FOXO3 protein aggressively upended the cancer cell’s survival programming. It formed a strong bond with STAT1, a known tumor suppressor. It subsequently increased the expression of PTEN (a major inhibitor of cell growth pathways) and FasL (a trigger for programmed cell death), while shutting down BCL6, an oncogene that normally protects cancer cells from dying. Furthermore, it upregulated SOD2, an enzyme that neutralizes mitochondrial oxidative stress.

The clinical implication is that longevity is not just governed by the presence or basic expression levels of FOXO genes, but by structural protein modifications that dictate their cellular localization and binding affinity. These evolutionary tweaks ensure the proteins remain highly active and situated in the nucleus, constantly surveying and suppressing oncogenic activity and oxidative damage.

Actionable Insights

The practical application of this research lies in mimicking the effects of the bowhead whale’s hyper-active FOXO variants. While human gene editing for these specific traits is not currently viable, individuals can target the downstream pathways identified in this paper to improve healthspan. The whale FOXO3 variant successfully upregulates PTEN and SOD2. Individuals can stimulate these same pathways via lifestyle interventions known to drive human FOXO3 into the nucleus, such as intermittent fasting, AMP-activated protein kinase (AMPK) activation, and hormetic stressors like cold exposure and hypoxia conditioning.

The magnitude of the benefit observed when these pathways are optimally activated is substantial. In the human cell models, replacing standard mammalian FOXO3 with the whale variant reduced cancer cell proliferation by approximately 53 percent relative to the mouse baseline (dropping from 32 percent to 15 percent EdU positive cells). It also reduced tumor cell invasion by nearly 60 percent (dropping from roughly 500 to 200 invading cells). By focusing on interventions that upregulate SOD2 for mitochondrial defense and PTEN for cell cycle regulation, health optimization strategies can replicate the mechanistic advantages of these evolutionary adaptations.

Context/Source

RapAdmin

RapalogixSkin
RapalogixSkin2752×1536 388 KB

A company-run, 12-week, double-blind trial in 47 women with moderate-to-severe facial photoaging tested a serum containing RLX-201, described as a selective mTORC1 inhibitor, against a vehicle. A blinded dermatologist graded firmness 21% better than baseline in the active group versus roughly 0% for vehicle, and radiance and texture gains were about twice those of vehicle. The instrument-measured difference was much smaller, and the headline “91% mTORC1 suppression” comes from lab-grown skin, not from the participants.

For a decade, longevity researchers have wondered whether the anti-aging effects of rapamycin could be captured in skin without swallowing an immunosuppressant. A 2019 Drexel University trial hinted that they could, showing that topical rapamycin lowered a senescence marker in the hands of older adults. Now a New York company, Rapalogix Health, reports the first controlled human trial of its own compound, RLX-201, which it describes as blocking only mTORC1, the half of the mTOR system tied to growth and suppressed cellular cleanup.

The trial enrolled 47 women aged 35 to 65 at a single North Carolina site. About two-thirds applied the RLX-201 serum twice daily and the rest applied a matching vehicle. Everyone also used the same SPF 30 moisturizer in the morning and a plain moisturizer at night. A dermatologist who did not know who got what scored each face at weeks 2, 4, 8 and 12.

On the primary measure, firmness, the active group improved 21% from baseline by week 12, while the vehicle group barely moved. Cheek wrinkles improved 21% against about 6%. Radiance, luminosity and texture improved 38 to 40%, against 15 to 18% for vehicle. No side effects were recorded in either group.

Those are respectable numbers for a cosmetic, but three things temper them. First, the vehicle group’s gains show how much a consistent sunscreen and moisturizer routine achieves alone: close to half of the headline radiance and texture improvement. Second, the only objective instrument in the trial, a suction device measuring skin mechanics, showed a far narrower gap. At week 12 the active group had changed 13% and the vehicle group 7%, and the paper’s own chart does not mark that difference as statistically significant, although the text says it was. The gap was widest at week 8 and shrank afterward, which sits awkwardly with the authors’ story of steadily accumulating structural repair.

There are disclosure problems. Three of the five authors work for Rapalogix, the company holds the copyright, and the serum is already on sale, yet the paper declares no conflicts of interest. The compound’s structure and concentration are not given.

The big idea is plausible and worth pursuing. Skin is the one human tissue where a longevity drug’s effect can be watched and biopsied directly. This paper shows a serum that outperformed its base on a dermatologist’s scorecard.

Actionable Insights

What the numbers mean in practice:

  • The firmness gain was 21% of baseline on a 0 to 4 grading scale. The paper does not report baseline scores, but for a typical moderate score that is roughly half a grade or less: visible to a trained eye, modest in a mirror.
  • For radiance and texture, the active serum delivered about 22 to 24 percentage points more improvement than vehicle (roughly 39% versus 16%). Sunscreen plus moisturizer alone produced the first 15 to 18 points.
  • On the instrument reading, the advantage was 6 percentage points (13% versus 7%), and this was not clearly distinguishable from chance at week 12.
  • The paper gives no standard deviations, so a proper standardized effect size cannot be calculated. Working backward from the sample size, the true benefit could plausibly range from trivial to large.

Take-home messages:

  • Daily SPF and moisturizer are the cheapest proven part of this protocol.
  • There is no comparison with retinoids, which have decades of histological evidence, so this is not grounds to replace them.
  • The 12-week safety data are reassuring but thin.
  • You can buy and try the Rapalogix product at this site: https://www.reqhealth.com

Context and Source

  • Open Access Paper: A Novel TORC1 Inhibitor, RLX-201, Improves Skin Health, Biomechanics, and Extracellular Matrix Integrity in a Double-Blind Clinical Study
  • Institutions: Dermatology Consulting Services (High Point, North Carolina); Rapalogix Health Inc. (New York); Day Dermatology and Aesthetics (New York)
  • Country: USA
  • Journal: Journal of Cosmetic Dermatology (Wiley)
  • Impact evaluation: The impact score of this journal is 2.5, evaluated against a typical high-end range of 0 to 12+ for top dermatology journals (0 to 60+ for top general science), therefore this is a Medium impact journal within its specialty.
  • Commercial context: Rapalogix Health is a spinout from Cambrian Bio, and RLX-201 is its proprietary small molecule. The Re-Q Pro-Longevity Face Serum is reported to have launched in May 2026, which is after the paper was submitted and before it was accepted.

相关阅读：

RapAdmin

SkinAgingOxidation
SkinAgingOxidation1672×940 200 KB

This review from Chinese military and university dermatology and plastic surgery groups sorts 47 classes of candidate skin anti-aging drugs by the biological mechanism they target: oxidative stress, telomere attrition, epigenetic drift, mitochondrial dysfunction, loss of proteostasis, and senescence-driven inflammation. The authors argue that oxidative stress is the central hub connecting all of these and should be the priority target. Their own evidence grading points elsewhere. The agents with real human trial support are topical tretinoin, retinaldehyde, niacinamide and, tentatively, low-dose topical rapamycin and urolithin A.

Skin is the one organ where anyone can watch aging happen, and the market for slowing it is enormous. A new review in Ageing Research Reviews tries to bring order to the field by asking what the candidate drugs actually act on, instead of simply listing them.

The authors searched PubMed and ClinicalTrials.gov through June 2026, started with 7,973 records, and ended with 91 reports covering 47 intervention classes. They organized these into six mechanistic domains and graded each on a five-level scale, from randomized human skin trials at the top to non-skin extrapolation at the bottom.

Their big idea is that oxidative stress sits at the center of the network. Reactive oxygen species damage telomeres and mitochondrial DNA, switch on the MAPK and NF-kB pathways that drive collagen-degrading enzymes and inflammation, and push cells into senescence. Senescent cells and failing mitochondria then generate more oxidants. On this view, oxidative stress is at once a trigger, an amplifier and a consequence, which makes it the logical place to intervene.

The catalogue is wide. It runs from familiar antioxidants such as vitamin C and N-acetylcysteine through Nrf2 activators like sulforaphane, NAD precursors, the mitophagy inducer urolithin A, sirtuin activators, telomerase activators, the mTOR inhibitor rapamycin, and senolytics such as navitoclax and dasatinib plus quercetin.

The compounds reaching the top evidence tier are mostly not antioxidants. Topical tretinoin, studied since the early 1990s, remains the benchmark: in a 24-week trial, 79 percent of users improved versus 48 percent on a dummy cream. Retinaldehyde and 5 percent niacinamide have smaller randomized trials behind them. Topical rapamycin has one small study showing fewer senescence markers in hand skin. Urolithin A cream cut wrinkle depth by about 6 percent in eight weeks.

Below that tier, the evidence thins quickly. NMN and NR raise NAD in blood, but no human trial has shown they improve wrinkles, elasticity or skin structure. Senolytics clear senescent cells in grafted human skin on mice, but they have no human skin-aging data and carry real toxicity, including platelet loss with navitoclax. The authors flag cancer concerns for telomerase activators and for sustained Nrf2 activation in sun-damaged skin.

The paper closes with a forward look: skin organoids for more realistic testing, microneedles and nanoparticle carriers to get drugs into the dermis, and AI-driven target discovery. These are plausible directions, but none has yet delivered a validated skin anti-aging drug.

The review is best read as a useful map, with clearly marked safety hazards, and not as proof of its central thesis. The oxidative stress hub is presented as a testable hypothesis, and the authors state what would falsify it. For now, the evidence-backed options are mostly the same ones dermatologists have recommended for years.

Actionable Insights

The practical message is that the proven options are old and inexpensive.

  • Tretinoin: in the main trial, 79 of every 100 users improved versus 48 of 100 on plain cream. That is 31 extra responders per 100, or roughly one extra person helped for every three treated. The 0.025 percent strength worked about as well as 0.1 percent with less redness and peeling. It is not for use in pregnancy.
  • Retinaldehyde: a gentler alternative. Wrinkle depth fell about 7.6 percent in eight weeks, a modest change.
  • Niacinamide 5 percent, twice daily: improved lines, texture and pigmentation over 12 weeks in 50 women, but the trial was industry funded and reported no numerical effect sizes.
  • Urolithin A cream: about a 6 percent reduction in wrinkle depth. This is measurable by instruments but probably hard to see in a mirror, and the data come from a manufacturer-run preprint.
  • Topical rapamycin: The research is still early. Promising but unproven.
  • Oral NMN, NR, sulforaphane, TA-65 and senolytics: no demonstrated human skin benefit.

The review barely discusses sunscreen, though ultraviolet light is the main trigger of the damage it describes.

Context/Source

  • Paywalled Paper: Research progress in skin anti-aging drugs based on core pathological drivers
  • Institutions: Yanbian University Hospital (Yanji); Fourth and Third Medical Centers of the Chinese PLA General Hospital (Beijing); Inner Mongolia Medical University (Hohhot); Beth Israel Deaconess Medical Center (Boston)
  • Countries: China, with one US co-author
  • Journal: Ageing Research Reviews, online 23 September 2026
  • Impact: The impact score of this journal is 12.4, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a High impact journal.

RapAdmin

DunedinPaceMemory-2
DunedinPaceMemory-22752×1536 433 KB

Subjective memory complaints in midlife serve as early warning signals for later cognitive decline and dementia. This longitudinal cohort study reveals that an accelerated pace of biological aging, measured via the DunedinPACE DNA methylation algorithm, prospectively predicts increased daily memory lapses and associated frustration a decade later, specifically for adults in their forties.

The measurement of biological age has shifted from static estimates of cumulative damage to dynamic quantifications of the ongoing pace of aging. First-generation epigenetic clocks predicted chronological age, whereas third-generation algorithms like DunedinPACE track the current speed of multisystem physiological deterioration. Researchers utilized this advanced epigenetic assessment to determine if the rate of biological aging precedes subtle, subjective cognitive complaints long before clinical mild cognitive impairment manifests.

The core investigation analyzed data from the Midlife in the United States (MIDUS) study, tracking participants who provided blood samples for DNA methylation profiling and subsequently reported daily memory lapses a decade later through the National Study of Daily Experiences. The research distinguished between prospective memory (forgetting to execute planned actions, such as taking medication) and retrospective memory (failing to recall past information, such as a name). These subtle cognitive disruptions often fall below the detection threshold of objective clinical tests but remain critical early indicators of cognitive vulnerability.

The findings isolate early midlife as a highly sensitive developmental window for neurological aging. The data establish no universal main effect linking epigenetic aging to memory lapses across all age groups. However, chronological age significantly moderates the relationship. For adults in their forties, a faster rate of biological aging robustly predicts an increase in prospective memory lapses ten years later, alongside greater irritation and interference with daily routines. This specific association disappears in older cohorts (individuals in their 60s and 70s), where cognitive decline may be driven by cumulative neuropathology rather than the current pace of systemic aging, or where older adults may simply lack the awareness of their cognitive lapses.

The implications suggest that cognitive decline is a downstream consequence of systemic physiological dysregulation that begins accumulating rapidly in midlife. Midlife introduces immense occupational and social stressors that accelerate biological aging. If the epigenetic pace of aging dictates the onset of subclinical cognitive deficits, interventions targeting systemic biological aging during the fourth decade of life represent a critical opportunity to alter the trajectory of neurodegeneration.

Actionable Insights

For individuals optimizing for healthspan, cognitive preservation requires systemic intervention decades before standard memory tests detect impairment [Confidence: High]. The data indicate that subjective cognitive complaints, such as forgetting why you walked into a room or failing to take a supplement, are not merely signs of distraction but are correlated with systemic biological aging.

The practical strength of this treatment effect is quantifiable. A DunedinPACE score above 1.0 indicates a faster-than-average aging rate. An individual with a score of 1.2 is aging 20% faster than the reference population. The authors report that a 10% increase in the rate of aging (a +0.10 shift in DunedinPACE) during a person’s forties indicates the occurrence of nearly one additional daily memory lapse a decade later.

To modify this trajectory, individuals must focus on the biomarkers that constitute the DunedinPACE algorithm. These include cardiopulmonary fitness, systemic inflammation (hsCRP), metabolic health (HbA1c, waist-to-hip ratio, lipid profiles), and periodontal health. Because DNA methylation is dynamic, optimizing these fundamental physiological markers in early midlife will decelerate the epigenetic pace of aging, directly mitigating downstream neurovascular and cognitive decline.

Context and Source

RapAdmin

RapArteries2
RapArteries22752×1536 462 KB

Atherosclerotic plaques expand dangerously when scavenger immune cells called macrophages fail to clear dying cells, a failure compounded by iron-driven oxidative cell damage known as ferroptosis. Examining both human endarterectomy tissues and mouse vascular models, researchers discovered that advanced plaques suffer from a severe breakdown in GPX4-mediated antioxidant defense, mitochondrial collapse, and loss of the clearance receptors MERTK and MFG-E8. Administering low-dose systemic rapamycin preserved mitochondrial energetics, suppressed iron-mediated lipid peroxidation, revived macrophage clearance capability, and cut whole-aorta plaque lipid burden by more than half while substantially increasing plaque-stabilizing collagen.

The defining crisis of advanced arterial disease is necrotic debris accumulation. As blood vessels accrue cholesterol, local macrophages ingest lipids until they become foam cells. In early stages, dying cells undergo efferocytosis, an orderly biological engulfment and waste-processing cycle that prevents intracellular contents from spilling into surrounding tissue. In mature lesions, this process falters. Uncleared apoptotic corpses undergo secondary necrosis, expelling inflammatory compounds, enzymatic debris, and crystalline lipids into the vessel wall. This cycle creates a growing, unstable necrotic core prone to catastrophic rupture.

A primary driver of this efferocytic collapse is ferroptosis, an iron-catalyzed cascade of lipid peroxidation that damages delicate subcellular membranes. Analyzing human carotid plaque samples harvested during vascular surgery, researchers observed that the primary lipid-peroxide neutralizer, glutathione peroxidase 4 (GPX4), was severely depleted in advanced fibrous lesions relative to adjacent early lesions. This deficiency leaves vascular macrophages defenseless against oxidative stress. Without functional GPX4, intracellular iron accelerates the peroxidation of polyunsaturated fatty acids, triggering mitochondrial calcium overload, membrane potential breakdown, and acute energy exhaustion. Because the mechanical engulfment of dying cells requires substantial cellular energy, energy-depleted macrophages shed their primary phagocytic tethering molecules, MERTK and MFG-E8.

The investigative team modeled this pathway in human macrophages using the chemical compound FIN-56, reproducing the cellular damage, glycolytic shift, and clearance deficits seen in diseased vessels. Co-treatment with rapamycin rescued these cellular cohorts. By dampening baseline mTOR activity, rapamycin restored GPX4 expression, lowered intracellular free iron and toxic lipid aldehydes, and preserved oxygen consumption and cellular energy production. Macrophages regained their physical capacity to bind and internalize dying cells. Crucially, the compound also stopped surrounding vascular smooth muscle cells from adopting a harmful synthetic phenotype that accelerates arterial disease.

In an animal model using genetically susceptible mice fed an atherogenic high-fat diet, a four-week regimen of twice-weekly rapamycin reversed established vascular decay. The treatment restored the ratio of active clearance events relative to free-floating dying cells from 0.37 to 1.37, while dropping lipid deposition across the entire length of the aorta from 25.32 percent down to 12.28 percent. Plaque coverage at the aortic root dropped from 35.56 percent to 16.71 percent, while protective fibrous collagen caps expanded from 22.42 percent to 39.73 percent. These findings indicate that rapamycin works in part by rescuing macrophage vitality and restoring cellular housekeeping.

Actionable Insights

This paper highlights that arterial plaque stability depends heavily on the energy status of tissue-resident macrophages and their capacity to clear cellular waste. The practical takeaway centers on the potential of targeted mTOR modulation and lipid antioxidant support to resolve vascular inflammation.

In mice, low-dose rapamycin produced an absolute reduction of 13.04 percentage points in aortic lipid accumulation (falling from 25.32% to 12.28%, a relative reduction of 51.5%), while reducing the aortic root plaque footprint by an absolute 18.85 percentage points (falling from 35.56% to 16.71%, a relative reduction of 53.0%). Concurrently, it produced an absolute increase of 17.31 percentage points in structural collagen (rising from 22.42% to 39.73%, a relative improvement of 77.2%), and improved the cellular clearance index nearly fourfold (increasing from 0.37 to 1.37).

These findings suggest that strategies preserving mitochondrial glutathione pools, minimizing systemic iron overload, and periodically attenuating hyperactive mTOR signaling may help stabilize existing plaques. The data also support the clinical development of drug-coated balloons that deliver rapamycin locally to damaged blood vessels, securing these cellular benefits without causing systemic harm.

Context and Source

  • Paywalled Paper: Rapamycin attenuates ferroptotic stress and improves macrophage efferocytosis in experimental atherosclerosis, 2026 Oct 2.
  • Primary Institutions: Department of Cerebrovascular Diseases, People’s Hospital of Zhengzhou University (Henan Provincial People’s Hospital); Henan International Joint Laboratory of Cerebrovascular Diseases, Zhengzhou, China
  • Journal Name: International Immunopharmacology
  • Impact Evaluation: The impact score of this journal is 5.6 (Clarivate Web of Science Journal Impact Factor), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

相关阅读：

RapAdmin

MSCSignalingStemCells-2
MSCSignalingStemCells-22752×1536 461 KB

This narrative review from Guangzhou argues that mesenchymal stem/stromal cells (MSCs) do not heal mainly by turning into new tissue. Instead, they act as short-lived signaling depots, releasing growth factors, immune-calming molecules and extracellular vesicles (EVs) that push the host’s own cells to repair. The authors survey clinical results in dental pulp and gum regeneration, osteoarthritis, spinal cord injury, lupus and graft-versus-host disease (GvHD). They conclude that inconsistent human results stem from donor variability, manufacturing problems and missing potency tests, and that the future lies in cell-free vesicle products and engineered cells.

For thirty years, the pitch for mesenchymal stem cells was simple: inject them, they travel to the damage, and they become the bone, cartilage or nerve you lost. A new review in Science Bulletin says that picture is largely wrong, and that the field has known it for some time.

The authors, a dental stem cell group at Sun Yat-sen University, describe a different mechanism. Injected MSCs mostly die. The review puts their working life in the body at under six hours and notes that transplanted cells undergo extensive apoptosis soon after delivery. What they leave behind is a burst of signals: proteins that grow blood vessels, molecules that quiet inflammation, and tiny membrane packets called extracellular vesicles that carry RNA and proteins into neighboring cells. On this view, the cell is a delivery vehicle and the cargo does the work.

That reframing explains a long-standing puzzle. MSC therapies look impressive in young, healthy lab animals with surgically created injuries, then deliver patchy results in older humans with chronic disease. If the benefit depends on how host tissue responds to a signal, the state of the host matters enormously. The review offers one telling example: tooth pulp regeneration with stem cells from baby teeth worked better in adolescents than in adults.

The clinical tour is sobering once the adjectives are removed. The strongest evidence is in GvHD, a dangerous complication of bone marrow transplants, where MSC products have regulatory approval in several countries. Even there, the headline result cited (an 82% response rate in 92 patients) came from a study with no control group, and a separate trial reported responses in only 36% of patients. In lupus, the foundational study had four patients. In spinal cord injury, the best figures come from uncontrolled case series. For osteoarthritis, the vesicle approach rests on one treated volunteer.

The dental work is the most concrete. Small randomized trials suggest that a patient’s own tooth-derived stem cells can regrow living pulp, with nerves and blood supply, inside a dead tooth, and can improve bone fill in gum disease. These are local, structural repairs that can be measured on a scan, which may be why they look cleaner than systemic uses.

Where does the field go next? The authors favor dropping the cell entirely and giving purified vesicles, including vesicles shed by dying cells, which they argue may be the true active ingredient. They also describe engineering tricks: starving cells of oxygen to change what they secrete, attaching targeting molecules so vesicles home to inflamed joints, and gene editing. One mouse study cut the required dose tenfold with a targeting tag.

The review is candid about what is missing: no agreed way to measure a product’s potency, large batch-to-batch differences, little long-term safety tracking, and few large blinded trials. Readers should treat this as a well-organized position paper from a group with a stake in vesicle and dental stem cell research, and not as a neutral verdict.

Insights

Practical points that follow:

  • Commercial “stem cell” infusions for general rejuvenation have no support here. The review’s own account is that injected cells are cleared within hours and that results vary widely between products and patients.
  • Evidence strength is ranked by condition. GvHD has approved products. Dental pulp and periodontal repair have small randomized trials. Osteoarthritis, spinal cord injury and lupus rest mostly on small or uncontrolled studies.
  • The size of the benefit is uncertain even in the best case. In GvHD, one uncontrolled study reported 82 of every 100 patients responding, while another trial reported 36 of every 100. That 46-point spread between studies is larger than most treatment effects in medicine, which tells you the product, patient mix and study design drive the number as much as the therapy does.
  • Host age matters. Regeneration worked better in adolescents than adults, which is a caution for older users expecting results seen in young subjects or animals.
  • Exosome and vesicle products remain experimental. Outside one GvHD case and one osteoarthritis case, the human evidence cited is essentially zero.

Context and Source

  • Paywalled Paper: Mesenchymal stem/stromal cells and regenerative medicine, 10 September 2026.
  • Institutions: Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University; Stomatological Hospital, Southern Medical University; Key Laboratory of Stem Cells and Tissue Engineering, Ministry of Education
  • Country: China (Guangzhou)
  • Journal: Science Bulletin (Elsevier and Science China Press),
  • Impact evaluation: The impact score of this journal is approximately 21 (2025 JIF, reported as 20.7 by one source and 21.1 by another), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

RapAdmin

PersonalizedAgingBlood
PersonalizedAgingBlood2752×1536 463 KB

A landmark longitudinal investigation tracking 335 women across an eight-year span has revealed that human biological aging does not follow a uniform, predetermined script. By analyzing whole-blood gene expression alongside serum metabolites over three distinct clinical visits, researchers uncovered that nearly a third of all monitored genes and an array of critical metabolites exhibit marked temporal shifts. Crucially, the trajectories of individual subjects frequently broke away from population averages, moving in diametrically opposed directions. Biological rhythmicity, environmental toxins, and host genetics interact continuously to shape these molecular paths, revealing that systemic decline is highly individualized rather than a synchronized march of chronological time.

Most of what we know about how human blood chemistry changes with age comes from comparing young people with old people at a single moment. That approach cannot separate real aging from the simple fact that people differ from one another. A study in Science takes the harder route: follow the same people and measure them again and again.

The MultiMuTHER project drew blood from 335 female twins aged 32 to 80 at three or more clinic visits between 2009 and 2017, a median of six years from first to last. Each sample was run for RNA sequencing of whole blood and for 915 usable serum metabolites.

The headline numbers are large. Expression of 5,036 genes, 31% of those measured, shifted consistently over time, split almost evenly between rising and falling. Among metabolites, only 45 (5%) showed a shared direction. Androgenic steroids such as DHEA-S fell, while ceramides and sphingomyelins, lipids tied to cardiometabolic risk, rose.

The more interesting result is how poorly the average describes the individual. Even for the genes with the strongest group trends, some women moved the opposite way and others barely moved. A further 136 metabolites, including serotonin and several acylcarnitines, changed substantially within people but in both directions, so the group average came out flat. The inflammatory chemokine gene CXCL9, a key component of a published inflammatory aging clock, behaved the same way.

Immune cells did not age in step either. Using computational estimates of cell-type-specific expression, the team found that CD4 and CD8 T cells mostly lost expression over time, while natural killer cells mostly gained it. The authors read this as remodeling of the immune system, with adaptive immunity waning and innate immunity turning up, although the cell-level data are inferred and not directly measured.

Context mattered a great deal. About 26% of genes and 39% of metabolites varied with the hour of the blood draw, even within office hours. A quarter of both varied with season, with interferon and immune genes peaking in winter. Genes that declined over time were about twice as long as those that rose, supporting earlier reports that aging blunts the transcription of long genes.

The study also caught an environmental policy at work. Serum levels of the “forever chemicals” PFOA and PFOS dropped steadily, in line with regulatory restrictions on their use. At the first visit PFOS tracked with the expression of 234 genes, including a thyroid hormone receptor gene. By the last visit no associations were detectable.

What the paper does not do is tell anyone which trajectory is good or bad. There are no disease or mortality outcomes, no men, and no non-European participants. Its value is as a reference map and as a warning: a single blood omics snapshot, compared against a population average, says less about a person’s aging than commercial test reports imply.

Actionable Insights

This study tested no treatment, so nothing here shows that changing a marker improves health. The practical lessons concern measurement.

First, one-off blood omics tests are noisy. A woman’s gene expression profile correlated only 0.31 with her own profile at another visit, on a scale where 1.0 is identical. That is about 10% shared variation. Metabolite profiles did better at 0.44 for adjacent visits, falling to 0.32 across the full span.

Second, standardize your blood draws. With 26% of genes and 39% of metabolites shifting by time of day, and about a quarter by season, a morning draw in January and an afternoon draw in July are not comparable. Same hour, same fasting state, and ideally the same season.

Third, track yourself, not the average. For 136 of the 181 changing metabolites (75%), people moved in both directions.

Fourth, body weight and blood sugar dominate. The strongest shared molecular pattern shifted about 0.09 standard deviations per BMI point, and women with type 2 diabetes sat roughly one standard deviation from healthy controls, a large gap.

Finally, PFAS blood levels fell after regulation, and their molecular associations disappeared. That is consistent with exposure reduction being worthwhile but does not prove a health benefit.

Context and Source

  • Paywalled Paper: Longitudinal dynamics of gene expression and metabolomics in an aging population cohort, September 2026.
  • Lead institution: Department of Twin Research and Genetic Epidemiology, King’s College London, with the University of Geneva, University of Oxford, and MRC Biostatistics Unit, Cambridge
  • Country: United Kingdom (lead), with Switzerland and Italy
  • Journal: Science, volume 393, issue 6815, 3 September 2026
  • Impact evaluation: The impact score of this journal is 47.3, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is an Elite impact journal.

RapAdmin

StemCellMuscle-2
StemCellMuscle-22752×1536 511 KB

This comprehensive review investigates the breakdown of skeletal muscle regeneration in aging and the structural barriers facing cell-based therapies. It concludes that the primary obstacle to restoring muscle tissue is not the exhaustion of localized stem cells themselves, but rather the toxic, inflammatory, and fibrotic degeneration of their surrounding microenvironment, requiring systemic conditioning before cellular therapies can succeed.

Skeletal muscle makes up roughly 40 percent of adult body mass and serves as a central hub for metabolic homeostasis, glucose regulation, and physical function. As organisms age, this tissue undergoes a catastrophic failure in regenerative capacity, clinically manifesting as sarcopenia. Historically, the longevity field viewed this functional decline as an isolated exhaustion of muscle satellite cells. The current review upends that model. It establishes that primary sarcopenia represents a systemic breakdown of the entire tissue microenvironment rather than just the intrinsic decay of localized stem cells.

This distinction dictates the future of cell therapy. Injecting healthy satellite cells into aged muscle yields remarkably poor engraftment. The aged skeletal muscle niche is actively hostile to regeneration. It is characterized by chronic inflammation driven by the senescence-associated secretory phenotype, significant biomechanical stiffening of the extracellular matrix, and profound vascular decay. Macrophages within this environment fail to execute the critical transition from a pro-inflammatory state to a tissue-reparative state. This immunological failure traps the muscle in a persistent fibrotic loop.

Because the microenvironment suppresses even youthful cells, researchers are pivoting to autologous cell therapies combined with systemic niche conditioning. Induced pluripotent stem cells and direct lineage reprogramming allow scientists to generate scalable patient-specific myogenic progenitors that reset the cellular epigenetic clock. Pluripotency protocols successfully bypass the historic expansion bottlenecks that rapidly degrade the stemness of primary cells. Yet evidence suggests these advanced cells only survive the aged environment rather than actively repairing the surrounding host tissue. True regeneration requires conditioning the host matrix prior to cellular intervention.

Exercise remains the most validated method for niche conditioning. Mechanical loading physically expands the satellite cell pool and reprograms the inflammatory landscape of the aged stem cell niche. Additionally, resolving systemic immune dysfunction is identified as a critical prerequisite. The review highlights how hematopoietic aging, specifically clonal hematopoiesis of indeterminate potential, drives chronic systemic inflammation that actively impairs localized muscle repair. Mutant immune clones flood the systemic circulation with inflammatory cytokines, reinforcing the local fibrotic blockade.

Muscle aging is not a localized structural failure but an integrated systemic collapse. The scientific community must deploy combinatorial strategies that pair advanced autologous stem cell grafts with microenvironmental remodeling to successfully restore contractile function in aging populations.

Their proposed answer has two halves. First, prepare the recipient: exercise, immune resetting, or biomaterial scaffolds that shelter the graft. Second, replace scarce primary cells with muscle progenitors grown from a patient’s own reprogrammed cells, which can be expanded without losing potency. One such product, MyoPAXon, has entered a first-in-human trial, though it was developed for muscular dystrophy and not for sarcopenia.

The authors add a caution. In every aged-animal study so far, the benefit comes from the graft itself. Nobody has checked whether the recipient’s own stem cells recover. The new cells appear to survive in old muscle without repairing it.

Insights

Nothing in this paper supports seeking cell therapy for age-related muscle loss today. There is no approved cell product for sarcopenia, and the review confirms that resistance exercise and nutrition remain the standard of care. Some key points to note:

  • Exercise physically alters the stem cell niche by restoring cell cycle regulators like Cyclin D1 and expanding the type II fiber satellite cell pool.
  • The magnitude of age-related decline is massive, with sarcopenia prevalence surging from between 5 and 13 percent in populations over 60, up to 50 percent in populations over 80.
  • Routine exercise physically intercepts this trajectory by maintaining mechanotransduction signals, mitigating an absolute risk increase of approximately 37 to 45 percent.
  • Aged muscle tissue experiences elevated CD38 NADase activity, resulting in severe intracellular NAD+ depletion.
  • Interventions that replenish NAD+ or restore basal autophagy directly rescue satellite cell senescence, transforming cells from an irreversible pre-senescent state back into functional stem cells.
  • Aged individuals with sarcopenia exhibit an approximate 20 percent reduction in capillary-to-fiber ratio compared to healthy peers.
  • Preserving cardiovascular integrity is structurally required for muscle maintenance because capillary endothelial cells provide critical angiocrine signals that sustain muscle stem cell dormancy.

Exercise is the only intervention discussed that a reader can use now. The review cites a human study in which twelve weeks of progressive resistance training expanded the stem cell pool on type II (fast) fibers, the subpopulation most depleted by aging. It gives no numbers for that gain, so the size of the benefit cannot be stated from this paper.

The figures it does report are sobering. In the best human satellite cell trials, donor cells produced working fibers in 3.5 to 21.2 percent of fibers, and only beside the injection track. Bone marrow transplant contributed donor nuclei to 0.5 to 0.9 percent of fibers. Sarcopenic older adults have about 20 percent fewer capillaries per fiber than non-sarcopenic peers, which is one more reason to maintain aerobic and resistance training.

MSC infusions improved physical performance in small frailty trials, but the review reports no magnitudes and the effect is transient. Clinics selling “stem cells for muscle” are running well ahead of this evidence.

Context and Source